Abstract
Little is known about the genetic regulation of medulloblastoma dissemination, but metastatic medulloblastoma is highly associated with poor outcome. We obtained expression profiles of 23 primary medulloblastomas clinically designated as either metastatic (M+) or non-metastatic (M0) and identified 85 genes whose expression differed significantly between classes. Using a class prediction algorithm based on these genes and a leave-one-out approach, we assigned sample class to these tumors (M+ or M0) with 72% accuracy and to four additional independent tumors with 100% accuracy. We also assigned the metastatic medulloblastoma cell line Daoy to the metastatic class. Notably, platelet-derived growth factor receptor α (PDGFRA) and members of the downstream RAS/mitogen-activated protein kinase (MAPK) signal transduction pathway are upregulated in M+ tumors. Immunohistochemical validation on an independent set of tumors shows significant overexpression of PDGFRA in M+ tumors compared to M0 tumors. Using in vitro assays, we show that platelet-derived growth factor α (PDGFA) enhances medulloblastoma migration and increases downstream MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK1 (p42 MAPK) and MAPK3 (p44 MAPK) phosphorylation in a dose-dependent manner. Neutralizing antibodies to PDGFRA blocks MAP2K1, MAP2K2 and MAPK1/3 phosphorylation, whereas U0126, a highly specific inhibitor of MAP2K1 and MAP2K2, also blocks MAPK1/3. Both inhibit migration and prevent PDGFA-stimulated migration. These results provide the first insight into the genetic regulation of medulloblastoma metastasis and are the first to suggest a role for PDGFRA and the RAS/MAPK signaling pathway in medulloblastoma metastasis. Inhibitors of PDGFRA and RAS proteins should therefore be considered for investigation as possible novel therapeutic strategies against medulloblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Packer, R.J. Childhood medulloblastoma: progress and future challenges. Brain Dev. 21, 75–81 (1999).
Packer, R.J. Brain tumors in children. Arch. Neurol. 56, 421–425 (1999).
Zeltzer, P.M. et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J. Clin. Oncol. 17, 832–845 (1999).
Grotzer, M.A. et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J. Clin. Oncol 18, 1027–1035 (2000).
Kim, J.Y. et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res. 59, 711–719 (1999).
Herms, J. et al. C-MYC expression in medulloblastoma and its prognostic value. Int. J. Cancer 89, 395–402 (2000).
Biegel, J.A. et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin. Cancer Res. 3, 473–478 (1997).
Batra, S.K. et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J. Neurooncol. 24, 39–45 (1995).
Emadian, S.M., McDonald, J.D., Gerken, S.C. & Fults, D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin. Cancer Res. 2, 1559–1564 (1996).
Golub, T.R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540 (2000).
Packer, R.J. et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J. Clin. Oncol. 17, 2127–2136 (1999).
Brown, H.G. et al. “Large cell/anaplastic” medulloblastomas: a Pediatric Oncology Group Study. J. Neuropathol. Exp. Neurol. 59, 857–865 (2000).
Adesina, A.M. Molecular heterogeneity in medulloblastoma with implications for differing tumor biology. J. Child Neurol. 14, 411–417 (1999).
Podust, V.N., Tiwari, N., Stephan, S. & Fanning, E. Replication factor C disengages from proliferating cell nuclear antigen (PCNA) upon sliding clamp formation, and PCNA itself tethers DNA polymerase delta to DNA. J. Biol. Chem. 273, 31992–31999 (1998).
Yuzhakov, A., Kelman, Z., Hurwitz, J. & O'Donnell, M. Multiple competition reactions for RPA order the assembly of the DNA polymerase delta holoenzyme. EMBO J. 18, 6189–6199 (1999).
Clark, E.A., Golub, T.R., Lander, E.S. & Hynes, R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532–535 (2000).
Kjoller, L. & Hall, A. Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-type Plasminogen Activator Receptor Binding to Vitronectin. J. Cell Biol. 152, 1145–1158 (2001).
Sunshine, C., Francis, S. & Kirk, K.L. Rab3B regulates ZO-1 targeting and actin organization in PC12 neuroendocrine cells. Exp. Cell Res. 257, 1–10 (2000).
Genda, D., Sakamoto, M., Ichida, T., Asakura, H. & Hirohashi, S. Loss of cell-cell contact is induced by integrin-mediated cell-substratum adhesion in highly-motile and highly-metastatic hepatocellular carcinoma cells. Lab. Invest. 80, 387–394 (2000).
Yi, M. & Ruoslahti, E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc. Natl Acad. Sci. USA 98, 620–624 (2001).
Felding-Haberman, B. et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl Acad. Sci. USA 98, 1853–1858 (2001).
Thomas, R., True, L.D., Bassuk, J.A., Lange, P.H. & Vessella, R.L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res. 6, 1140–1149 (2000).
Remacle, A. et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int. J. Cancer 89, 118–121 (2000).
McCarthy, M.J., Crowther, M., Bell, P.R. & Brindle, N.P. The endothelial receptor tyrosine kinase tie-1 is upregulated by hypoxia and vascular endothelial growth factor. FEBS Lett. 423, 334–338 (1998).
Cillo, C., Cantile, M., Mortarini, R., Barba, P., Parmiani, P. & Anichini, A. Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. Int. J. Cancer 66, 692–697 (1996).
Garson, J.A., Pemberton, L.F., Sheppard, P.W., Varndell, I.M., Coakham, H.B. & Kemshead, J.T. N-myc gene expression and oncoprotein characterisation in medulloblastoma. Br. J. Cancer 59, 889–894 (1989).
Zurawel, R.H. et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosom. Cancer 27, 44–51 (2000).
Gilbertson, R.J., Pearson, A.D., Perry, R.H., Jaros, E. & Kelly, P.J. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br. J. Cancer. 71, 473–477 (1995).
Huang, H., Colella, S., Kurrer, M., Yonekawa, Y., Kleihues, P. & Ohgaki, H. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 60, 6868–6874 (2000).
Markert, J.M. et al. Differential gene expression profiling in human brain tumors. Physiol. Genomics 5, 21–33 (2001).
Ellison, J.A. & de Vellis, J. Platelet-derived growth factor is expressed by cells in the early oligodendrocyte lineage. J. Neurosci. Res. 37, 116–128 (1994).
Yu, J., Deuel, T.F. & Kim, H.R. Platelet-derived growth factor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-beta-induced phenotypic transformation. J. Biol. Chem. 275, 19076–19082 (2000).
Sieg, D.J. et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nature Cell Biol. 2, 249–256 (2000).
Yao, R., Yoshihara, M. & Osada, H. Specific activation of a c-Jun NH2-terminal kinase isoform and induction of neurite outgrowth in PC-12 cells by staurosporine. J. Biol. Chem. 272, 18261–18266 (1997).
Khan, J., Bittner, M., Chen, Y., Meltzer, P. & Trent, J.T. DNA microarray technology: the anticipated impact on the study of human disease. Biochim. Biophys. Acta. 1423, 17–28 (1999).
Eisen, M.B., Spellman, P.T., Brown, P.O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863–14868 (1998).
Ben-Dor, A., Friedman, N. & Yakhini, Z. Scoring Genes for Relevence. Report No. AGL-2000-12 (Agilent Labs, Palo Alto, California, 2000).
Acknowledgements
This research was supported in part by the Children's Brain Tumor Foundation (T.J.M.) as well as an Avery Research Scholarship (T.J.M.) and Child Health Research Career Development Award (T.J.M.) from the Children's Research Institute of the Children's Hospital National Medical Center. The authors thank A. Butte, P. Tamayo, E. Hoffman, D. Dressman, J. Natale and Y. Liu for technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
MacDonald, T., Brown, K., LaFleur, B. et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29, 143–152 (2001). https://doi.org/10.1038/ng731
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng731
This article is cited by
-
ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
Nature Communications (2023)
-
Targeting Angiogenic Factors for the Treatment of Medulloblastoma
Current Treatment Options in Oncology (2022)
-
Ten-eleven translocation protein 1 modulates medulloblastoma progression
Genome Biology (2021)
-
Integrated computational analyses reveal novel insights into the stromal microenvironment of SHH-subtype medulloblastoma
Scientific Reports (2021)
-
AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development
Cell Death & Disease (2021)